Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ScTIL
- Development stage
- Phase 2
- Lead developer
- Peking University Cancer Hospital & Institute
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
ScTIL is a cell therapy that utilizes genetically modified tumor-infiltrating lymphocytes (TILs). It is being investigated for its safety, pharmacokinetic characteristics, and efficacy in the treatment of various recurrent or refractory gynecological malignancies, advanced malignant solid tumors, melanoma, and digestive system malignant solid tumors. The therapy aims to induce an anti-tumor immune response.
- Other names
- Genetically Modified Tumor Infiltrating LymphocytesSuper circulating tumor infiltrating lymphocytes
Beyond the preview
Go deeper on ScTIL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ScTIL.